Panacea, Sanofi settle patent litigation over hexavalent vaccine

Panacea Biotec has settled a patent infringement case with Sanofi Healthcare India over a hexavalent vaccine. Sanofi will not launch its Shan6 vaccine in India and will withdraw its opposition to Panacea's patent. Panacea will forgo claims for damages. The Delhi High Court disposed of the suit on September 13, 2024.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yIdrseM
via IFTTT